Literature DB >> 15864880

Skin tests with native, depigmented and glutaraldehyde polymerized allergen extracts.

M Casanovas1, M J Gómez, J Carnés, E Fernández-Caldas.   

Abstract

INTRODUCTION: Dose-response skin prick tests are an important tool to standardise allergen extracts and to evaluate changes in skin test response as a consequence of allergen modifications.
OBJECTIVES: To evaluate in vivo and in vitro characteristics of 3 different types of extracts of Phleumpratense, Olea europaea, Parietaria judaica and Dermatophagoides pteronyssinus.
MATERIAL AND METHODS: Three types of extracts were used: native unmodified extracts (N), depigmented extracts (DP) (extracts subjected to a mild acid treatment under controlled conditions and dialysis), and a depigmented glutaraldehyde polymerised extract (DPP). Adult patients were skin tested in duplicate with the 3 types of extracts. The dose-response relationship between the geometric mean of the wheal areas and the allergen concentrations was calculated for each patient using regression line analysis. The amount of freeze-dried allergen preparation needed to produce the same wheal size as histamine was calculated in each patient (individual 10 HEP) and for each of the 3 types of extracts. In vitro analysis consisted of major allergen determinations and specific IgE and IgG inhibitions.
RESULTS: The respective 10 HEP values for N, DP and DPP preparations were 0.20 mg, 0.15 and 2.11 for D. pteronyssinus. For P. pratense, these values were 0.02 mg, 0.02 and 0.99; for O. europaea 0.15, 0.44 and 4.9; and for P. judaica 0.01, 0.008 and 1.78 mg.
CONCLUSIONS: The polymerised depigmented extracts are significantly less allergenic than the corresponding native and depigmented extracts. This could provide a greater safety margin for the administration of higher doses of immunotherapy in a shorter period of time.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15864880

Source DB:  PubMed          Journal:  J Investig Allergol Clin Immunol        ISSN: 1018-9068            Impact factor:   4.333


  7 in total

1.  [Specific immunotherapy with depigmented allergoids].

Authors:  L Klimek; C Thorn; O Pfaar
Journal:  HNO       Date:  2010-01       Impact factor: 1.284

Review 2.  Control Process for Manufacturing and Standardization of Allergenic Molecules.

Authors:  Jerónimo Carnés; Víctor Iraola; Mayte Gallego; Jose R Leonor
Journal:  Curr Allergy Asthma Rep       Date:  2015-07       Impact factor: 4.806

3.  Safety and effect on reported symptoms of depigmented polymerized allergen immunotherapy: a retrospective study of 2927 paediatric patients.

Authors:  Oliver Pfaar; Angelika Sager; Douglas S Robinson
Journal:  Pediatr Allergy Immunol       Date:  2015-05       Impact factor: 6.377

4.  House dust mite-specific immunotherapy with two licensed vaccines: Outcome under clinical routine conditions.

Authors:  Vera Mahler; Christian Klein; Angelika Sager; Jürgen Zimmermann
Journal:  Immun Inflamm Dis       Date:  2017-03-05

Review 5.  Novel strategies in immunotherapy for allergic diseases.

Authors:  Mohana Rajakulendran; Elizabeth Huiwen Tham; Jian Yi Soh; H P Van Bever
Journal:  Asia Pac Allergy       Date:  2018-04-09

6.  Depigmented allergoids reveal new epitopes with capacity to induce IgG blocking antibodies.

Authors:  M Angeles López-Matas; Mayte Gallego; Víctor Iraola; Douglas Robinson; Jerónimo Carnés
Journal:  Biomed Res Int       Date:  2013-10-08       Impact factor: 3.411

7.  Depigmented-polymerised allergoids favour regulatory over effector T cells: enhancement by 1α, 25-dihydroxyvitamin D3.

Authors:  Zoe L Urry; David F Richards; Cheryl Black; Maria Morales; Jerónimo Carnés; Catherine M Hawrylowicz; Douglas S Robinson
Journal:  BMC Immunol       Date:  2014-05-29       Impact factor: 3.615

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.